What is the MELD (Model for End‑Stage Liver Disease) score, how is it calculated, and what thresholds indicate significant transplant urgency?

MELD Score: Definition, Calculation, and Transplant Urgency Thresholds

What the MELD Score Is

The MELD (Model for End-Stage Liver Disease) score is a validated, objective scoring system that predicts 3-month mortality in patients with end-stage liver disease and serves as the primary tool for prioritizing liver transplant allocation in most countries. 1, 2

• The score was originally developed to predict survival following transjugular intrahepatic portosystemic shunt (TIPS) procedures, but was subsequently validated as an accurate predictor of mortality in patients with end-stage liver disease 3, 4

• MELD provides a continuous numerical scale ranging from 6 to 40, with higher scores correlating with increased mortality risk 2, 3

How MELD is Calculated

The MELD score incorporates three objective laboratory parameters: serum bilirubin (mg/dL), international normalized ratio (INR), and serum creatinine (mg/dL). 1, 2

The calculation formula is: 2

MELD = 3.8 × ln(bilirubin mg/dL) + 11.2 × ln(INR) + 9.6 × ln(creatinine mg/dL) + 6.4

Key Calculation Details:

• Minimum values are set at 1.0 for each laboratory parameter to avoid negative logarithms 2
• Maximum creatinine is capped at 4.0 mg/dL for patients on dialysis or who have received dialysis twice in the past week 2
• The final score is rounded to the nearest whole number 2

Mortality Risk by MELD Score:

• MELD 6-9: ~2-3% three-month mortality 2
• MELD 10-14: ~6% three-month mortality 2
• MELD 15-19: ~20-30% three-month mortality 2
• MELD 20-29: ~30-50% three-month mortality 2
• MELD 30-40: ~50-70% three-month mortality 2

Critical Transplant Urgency Thresholds

MELD ≥15 is the recommended threshold for listing patients for liver transplantation, as patients with MELD ≤14 have better 1-year survival without transplantation than with it. 1, 2

Management Algorithm Based on MELD Score:

For MELD ≥15 (High Transplant Urgency): 2

• Immediately refer for liver transplantation evaluation
• Engage multidisciplinary transplant team
• Screen for hepatocellular carcinoma (may qualify for exception points)
• Monitor for acute decompensation events: ascites, hepatic encephalopathy, variceal bleeding, spontaneous bacterial peritonitis, hepatorenal syndrome
• Serially assess renal function (rising creatinine markedly increases MELD)
• Reassess MELD score every 1-2 weeks

For MELD 10-14 (Moderate Risk): 2

• Monitor for disease progression with MELD reassessment every 3-6 months
• Screen for and manage cirrhosis complications (varices, ascites, encephalopathy)
• Consider transplant evaluation if MELD rises to ≥15 or major complications develop

For MELD <10 (Lower Risk): 2

• Focus on treating underlying liver disease and preventing progression
• Monitor MELD every 6-12 months
• Manage specific complications as they arise

Important Limitations and Exceptions

MELD Exceptions Requiring Additional Points:

Certain conditions warrant "exception points" because MELD inadequately reflects their mortality risk or transplant benefit: 1, 2

• Hepatocellular carcinoma (HCC) within Milan criteria
• Hepatopulmonary syndrome
• Portopulmonary hypertension
• Primary hyperoxaluria
• Familial amyloidosis
• Refractory ascites unresponsive to medical therapy
• Recurrent cholangitis in primary sclerosing cholangitis

Critical Pitfalls to Avoid:

Serum creatinine can be unreliable in cirrhotic patients: 2

• Overestimates renal dysfunction in patients with sarcopenia (low muscle mass)
• Underestimates dysfunction in patients with fluid overload
• May be artificially elevated in patients on certain medications

INR exhibits significant inter-laboratory variability and was originally designed for warfarin monitoring, not liver disease assessment. 2

MELD does not capture critical clinical variables that significantly affect prognosis: 1, 2

• Ascites severity
• Hepatic encephalopathy grade
• Nutritional status and sarcopenia
• Frailty
• Variceal bleeding history

Very high MELD scores (>30-35) are associated with increased post-transplant mortality and morbidity, requiring careful assessment of transplant candidacy. 2

Enhanced MELD Variations

MELD-Na (MELD-Sodium):

MELD-Na incorporates serum sodium to improve mortality prediction, particularly in patients with low MELD scores where hyponatremia may not be adequately captured. 1

• Hyponatremia (sodium <130 mmol/L) is an independent predictor of death in cirrhotic patients with ascites 2
• MELD-Na is currently used for organ allocation in the United States 2

MELD 3.0 (Most Recent Version):

MELD 3.0 incorporates patient sex and serum albumin to reduce gender disparities and improve mortality prediction, with women receiving approximately 1.3 additional points. 1, 5

• Demonstrates superior discrimination compared to MELD-Na (C-statistic 0.869 vs 0.862, p<0.01) 1, 5
• Correctly reclassifies 8.8% of patients to higher MELD tiers, particularly benefiting women 1, 5
• Results in fewer waitlist deaths compared to MELD-Na in simulation models 1, 5
• Not yet widely implemented in clinical practice as of 2024 1

Delta MELD:

Delta MELD measures the change in MELD score over time and may be a better predictor of mortality than a single MELD value. 1

Common Clinical Pitfalls

Do not delay transplant referral while awaiting further clinical deterioration when MELD ≥15. 2

Do not rely on MELD alone in patients with HCC or other conditions that merit exception points. 2

Do not ignore clinical decompensation (ascites, encephalopathy, variceal bleeding) even if the MELD score appears borderline. 2

Do not transfuse plasma solely to "correct" the INR in non-bleeding patients, as the INR serves primarily as a prognostic marker and transfusion provides no clinical benefit. 2

Recognize that female patients may have worse outcomes than predicted by MELD alone due to gender-related disparities in the scoring system. 1